MiMedx Group, Inc. (NASDAQ:MDXG) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. trimmed its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 4.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 807,373 shares of the company’s stock after selling 35,247 shares during the period. Federated Hermes Inc.’s holdings in MiMedx Group were worth $7,081,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MDXG. Cannell Capital LLC grew its position in MiMedx Group by 106.7% in the 3rd quarter. Cannell Capital LLC now owns 2,273,762 shares of the company’s stock valued at $16,576,000 after buying an additional 1,173,506 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of MiMedx Group by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 6,437,155 shares of the company’s stock worth $46,927,000 after acquiring an additional 250,812 shares during the period. Turtle Creek Wealth Advisors LLC bought a new position in shares of MiMedx Group in the fourth quarter valued at approximately $1,594,000. Jupiter Asset Management Ltd. bought a new position in shares of MiMedx Group in the third quarter valued at approximately $1,264,000. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of MiMedx Group by 354.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 197,943 shares of the company’s stock valued at $1,443,000 after acquiring an additional 154,376 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MDXG has been the subject of a number of research analyst reports. Mizuho upped their target price on MiMedx Group from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Lake Street Capital started coverage on MiMedx Group in a report on Thursday, March 7th. They issued a “buy” rating and a $12.00 price objective for the company. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $12.25.

MiMedx Group Stock Down 1.2 %

MDXG stock opened at $6.43 on Thursday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.57 and a quick ratio of 3.11. The firm has a market cap of $944.95 million, a PE ratio of 20.09 and a beta of 1.32. MiMedx Group, Inc. has a 12 month low of $3.49 and a 12 month high of $9.27. The firm has a 50 day simple moving average of $7.54 and a 200 day simple moving average of $7.57.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The company had revenue of $86.83 million for the quarter, compared to analyst estimates of $85.58 million. MiMedx Group had a net margin of 14.49% and a return on equity of 41.12%. Equities research analysts forecast that MiMedx Group, Inc. will post 0.33 earnings per share for the current fiscal year.

Insider Activity

In other MiMedx Group news, COO Ricci S. Whitlow sold 15,493 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $8.07, for a total transaction of $125,028.51. Following the sale, the chief operating officer now owns 416,321 shares in the company, valued at approximately $3,359,710.47. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, COO Ricci S. Whitlow sold 15,271 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $8.01, for a total value of $122,320.71. Following the completion of the sale, the chief operating officer now owns 401,050 shares in the company, valued at $3,212,410.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Ricci S. Whitlow sold 15,493 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $8.07, for a total value of $125,028.51. Following the completion of the sale, the chief operating officer now directly owns 416,321 shares of the company’s stock, valued at approximately $3,359,710.47. The disclosure for this sale can be found here. Insiders sold a total of 51,145 shares of company stock valued at $409,378 over the last three months. Insiders own 19.90% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.